Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human corneal endothelium
- Molecular classification
- Other (specialized post-mitotic epithelial-like cell layer; not classified as receptor, enzyme, channel, etc.)
01
Overview
The human corneal endothelium is a monolayer of highly specialized, hexagonal, terminally differentiated cells that line the posterior surface of the cornea, adjacent to the aqueous humor. These cells play a crucial physiological role in maintaining corneal hydration and clarity by regulating the fluid and solute transport between the aqueous humor and corneal stroma through a combination of a leaky barrier and ion pumps, principally Na^+/K^+-ATPase and carbonic anhydrase. The cells are of neural crest origin, are post-mitotic (do not readily divide to repair damage), and loss beyond a critical threshold leads to corneal swelling (edema) and visual impairment. They are a focus of regenerative cell therapies but are not a canonical druggable molecular target in the conventional sense.
- Other names
- Corneal endotheliumCorneal endothelial cells (CECs)
02
Mechanism of action
Not applicable (no approved drugs with direct molecular targeting of this cell layer)
03
Biological functions
Regulation of corneal hydration and transparencyFluid and solute transport (maintenance of corneal deturgescence)Barrier formation between aqueous humor and corneal stromaActive metabolic pumping (principally via Na^+/K^+-ATPase and carbonic anhydrase)
04
Disease associations
Corneal edema (and loss of transparency)Corneal endothelial dystrophies (e.g., Fuchs’ endothelial dystrophy)Post-surgical or traumatic corneal endothelial cell lossOther (roles in graft rejection in corneal transplantation)
05
Safety considerations
Inability of human corneal endothelium to proliferate in vivo; loss is permanentRisk of chronic corneal edema, decompensation, and vision loss after cell lossImmunogenicity concerns in corneal transplantation (e.g., graft rejection)
06
Interacting drugs
None specific to corneal endothelial cells as a molecular drug target; however, carbonic anhydrase inhibitors and Na^+/K^+-ATPase inhibitors can affect cell function in experimental models but are not targeted therapies
07
Biomarkers
Endothelial cell density (measured by specular microscopy)Expression of Na^+/K^+-ATPase, N-cadherin, ZO-1, AQP1
Beyond the preview
Go deeper on Human corneal endothelium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Human corneal endothelium.